George Rehm
Direktor/Vorstandsmitglied bei Barnev, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Stefan Herr | M | - |
EMBL Ventures GmbH
EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | 23 Jahre |
Frank Mühlenbeck | M | 53 |
firstVentury Equity GmbH
Calibrium Private Investments GmbH
Calibrium Private Investments GmbH Investment ManagersFinance Calibrium Private Investments GmbH (formerly Aeris Capital AG) is a venture capital firm with headquarters in Zurich, Switzerland. The firm was founded in 2006.
EMBL Ventures GmbH
EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | 24 Jahre |
Jonathan Rothberg | M | 60 |
AI Therapeutics, Inc.
AI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT. | - |
Jonathan Adereth | M | 77 |
Barnev, Inc.
Barnev, Inc. Information Technology ServicesTechnology Services Barnev, Inc. is a healthcare information technology company specializing in the development, manufacturing, and marketing of comprehensive monitoring and information solutions to clinicians and hospitals for labor and delivery. The firm is the first to market with delivery suite/product solutions that improve the clinical management of patients, and improve economic efficiency for its customers. Its first product, the BirthTrack™ Continuous Labor Monitoring System, is the most exciting innovation in labor progression monitoring since the Friedman Labor Curve was introduced over 50 years ago. The BirthTrack System is a revolutionary continuous labor monitoring technology that provides obstetric caregivers invaluable, precise, objective, real-time information about the physical progress of labor. | 24 Jahre |
Michael Lusting | M | - |
Inkspace Imaging, Inc.
Inkspace Imaging, Inc. Medical SpecialtiesHealth Technology Inkspace Imaging, Inc. develops magnetic resonance imaging surface receive coils. The company was founded by Ana Claudia Arias, Michael Lustingis and Joseph Corea in 2016 and is headquartered in Pleasanton, CA. | 8 Jahre |
James F. Puffenberger | M | - |
Barnev, Inc.
Barnev, Inc. Information Technology ServicesTechnology Services Barnev, Inc. is a healthcare information technology company specializing in the development, manufacturing, and marketing of comprehensive monitoring and information solutions to clinicians and hospitals for labor and delivery. The firm is the first to market with delivery suite/product solutions that improve the clinical management of patients, and improve economic efficiency for its customers. Its first product, the BirthTrack™ Continuous Labor Monitoring System, is the most exciting innovation in labor progression monitoring since the Friedman Labor Curve was introduced over 50 years ago. The BirthTrack System is a revolutionary continuous labor monitoring technology that provides obstetric caregivers invaluable, precise, objective, real-time information about the physical progress of labor. | - |
Joseph Corea | M | - |
Inkspace Imaging, Inc.
Inkspace Imaging, Inc. Medical SpecialtiesHealth Technology Inkspace Imaging, Inc. develops magnetic resonance imaging surface receive coils. The company was founded by Ana Claudia Arias, Michael Lustingis and Joseph Corea in 2016 and is headquartered in Pleasanton, CA. | 8 Jahre |
Stan Chudnovsky | M | 53 |
Jiff, Inc.
Jiff, Inc. Packaged SoftwareTechnology Services Jiff, Inc. provides mobile based consumer-centric software platform for the healthcare industry. It provides an enterprise solution for self-insured employers to connect to and manage digital health tools, and to provide each employee with an individualized health incentives program. The firm’s HIPAA-compliant platform helps companies connect their health benefit design and incentives to the consumer digital health applications, devices, and services that employees know. The company was founded in 2010 by James P. Currier and Stan Chudnovsky and is headquartered in Palo Alto, CA. | 14 Jahre |
Rachel Sherman | F | - |
Jiff, Inc.
Jiff, Inc. Packaged SoftwareTechnology Services Jiff, Inc. provides mobile based consumer-centric software platform for the healthcare industry. It provides an enterprise solution for self-insured employers to connect to and manage digital health tools, and to provide each employee with an individualized health incentives program. The firm’s HIPAA-compliant platform helps companies connect their health benefit design and incentives to the consumer digital health applications, devices, and services that employees know. The company was founded in 2010 by James P. Currier and Stan Chudnovsky and is headquartered in Palo Alto, CA. | - |
Ronald P. Weidner | M | - |
emPower Health Equity, Inc.
emPower Health Equity, Inc. Medical/Nursing ServicesHealth Services emPower Health Equity, Inc. provides healthcare services. The company is headquartered in Tiburon, CA. | - |
Paul Boni | M | - |
AI Therapeutics, Inc.
AI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT. | - |
Brigette Roberts | M | - |
AI Therapeutics, Inc.
AI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT. | - |
Andrew Mason | M | - |
emPower Health Equity, Inc.
emPower Health Equity, Inc. Medical/Nursing ServicesHealth Services emPower Health Equity, Inc. provides healthcare services. The company is headquartered in Tiburon, CA. | - |
David Scheer | M | - |
AI Therapeutics, Inc.
AI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT. | 1 Jahre |
Murat Gunel | M | - |
AI Therapeutics, Inc.
AI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT. | - |
Vikram Khanna | M | - |
AI Therapeutics, Inc.
AI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT. | - |
Cornelia Brosi | M | - |
EMBL Ventures GmbH
EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | 6 Jahre |
Caroline Sauer | F | - |
EMBL Ventures GmbH
EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | 8 Jahre |
Peter Fischer | M | - |
Inkspace Imaging, Inc.
Inkspace Imaging, Inc. Medical SpecialtiesHealth Technology Inkspace Imaging, Inc. develops magnetic resonance imaging surface receive coils. The company was founded by Ana Claudia Arias, Michael Lustingis and Joseph Corea in 2016 and is headquartered in Pleasanton, CA. | 5 Jahre |
John Kemmerer | M | - |
Jiff, Inc.
Jiff, Inc. Packaged SoftwareTechnology Services Jiff, Inc. provides mobile based consumer-centric software platform for the healthcare industry. It provides an enterprise solution for self-insured employers to connect to and manage digital health tools, and to provide each employee with an individualized health incentives program. The firm’s HIPAA-compliant platform helps companies connect their health benefit design and incentives to the consumer digital health applications, devices, and services that employees know. The company was founded in 2010 by James P. Currier and Stan Chudnovsky and is headquartered in Palo Alto, CA. | - |
Johnathan Hodge | M | - |
Jiff, Inc.
Jiff, Inc. Packaged SoftwareTechnology Services Jiff, Inc. provides mobile based consumer-centric software platform for the healthcare industry. It provides an enterprise solution for self-insured employers to connect to and manage digital health tools, and to provide each employee with an individualized health incentives program. The firm’s HIPAA-compliant platform helps companies connect their health benefit design and incentives to the consumer digital health applications, devices, and services that employees know. The company was founded in 2010 by James P. Currier and Stan Chudnovsky and is headquartered in Palo Alto, CA. | - |
Karl Steigele | M | - |
Barnev, Inc.
Barnev, Inc. Information Technology ServicesTechnology Services Barnev, Inc. is a healthcare information technology company specializing in the development, manufacturing, and marketing of comprehensive monitoring and information solutions to clinicians and hospitals for labor and delivery. The firm is the first to market with delivery suite/product solutions that improve the clinical management of patients, and improve economic efficiency for its customers. Its first product, the BirthTrack™ Continuous Labor Monitoring System, is the most exciting innovation in labor progression monitoring since the Friedman Labor Curve was introduced over 50 years ago. The BirthTrack System is a revolutionary continuous labor monitoring technology that provides obstetric caregivers invaluable, precise, objective, real-time information about the physical progress of labor. | - |
Pierce W. Graham-Jones | M | - |
Jiff, Inc.
Jiff, Inc. Packaged SoftwareTechnology Services Jiff, Inc. provides mobile based consumer-centric software platform for the healthcare industry. It provides an enterprise solution for self-insured employers to connect to and manage digital health tools, and to provide each employee with an individualized health incentives program. The firm’s HIPAA-compliant platform helps companies connect their health benefit design and incentives to the consumer digital health applications, devices, and services that employees know. The company was founded in 2010 by James P. Currier and Stan Chudnovsky and is headquartered in Palo Alto, CA. | - |
Himgan Wibisono | M | - |
Jiff, Inc.
Jiff, Inc. Packaged SoftwareTechnology Services Jiff, Inc. provides mobile based consumer-centric software platform for the healthcare industry. It provides an enterprise solution for self-insured employers to connect to and manage digital health tools, and to provide each employee with an individualized health incentives program. The firm’s HIPAA-compliant platform helps companies connect their health benefit design and incentives to the consumer digital health applications, devices, and services that employees know. The company was founded in 2010 by James P. Currier and Stan Chudnovsky and is headquartered in Palo Alto, CA. | - |
Bob Kocher | M | 52 |
Jiff, Inc.
Jiff, Inc. Packaged SoftwareTechnology Services Jiff, Inc. provides mobile based consumer-centric software platform for the healthcare industry. It provides an enterprise solution for self-insured employers to connect to and manage digital health tools, and to provide each employee with an individualized health incentives program. The firm’s HIPAA-compliant platform helps companies connect their health benefit design and incentives to the consumer digital health applications, devices, and services that employees know. The company was founded in 2010 by James P. Currier and Stan Chudnovsky and is headquartered in Palo Alto, CA. | - |
Jason Pyle | M | - |
emPower Health Equity, Inc.
emPower Health Equity, Inc. Medical/Nursing ServicesHealth Services emPower Health Equity, Inc. provides healthcare services. The company is headquartered in Tiburon, CA. | - |
Rainer Wessel | M | 63 |
EMBL Ventures GmbH
EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | - |
Christopher B. Kuenne | M | - |
Jiff, Inc.
Jiff, Inc. Packaged SoftwareTechnology Services Jiff, Inc. provides mobile based consumer-centric software platform for the healthcare industry. It provides an enterprise solution for self-insured employers to connect to and manage digital health tools, and to provide each employee with an individualized health incentives program. The firm’s HIPAA-compliant platform helps companies connect their health benefit design and incentives to the consumer digital health applications, devices, and services that employees know. The company was founded in 2010 by James P. Currier and Stan Chudnovsky and is headquartered in Palo Alto, CA. | - |
Darren Hite | M | - |
Jiff, Inc.
Jiff, Inc. Packaged SoftwareTechnology Services Jiff, Inc. provides mobile based consumer-centric software platform for the healthcare industry. It provides an enterprise solution for self-insured employers to connect to and manage digital health tools, and to provide each employee with an individualized health incentives program. The firm’s HIPAA-compliant platform helps companies connect their health benefit design and incentives to the consumer digital health applications, devices, and services that employees know. The company was founded in 2010 by James P. Currier and Stan Chudnovsky and is headquartered in Palo Alto, CA. | - |
Douglas Smith | M | - |
Barnev, Inc.
Barnev, Inc. Information Technology ServicesTechnology Services Barnev, Inc. is a healthcare information technology company specializing in the development, manufacturing, and marketing of comprehensive monitoring and information solutions to clinicians and hospitals for labor and delivery. The firm is the first to market with delivery suite/product solutions that improve the clinical management of patients, and improve economic efficiency for its customers. Its first product, the BirthTrack™ Continuous Labor Monitoring System, is the most exciting innovation in labor progression monitoring since the Friedman Labor Curve was introduced over 50 years ago. The BirthTrack System is a revolutionary continuous labor monitoring technology that provides obstetric caregivers invaluable, precise, objective, real-time information about the physical progress of labor. | 17 Jahre |
Heinz Schwer | M | 57 |
EMBL Ventures GmbH
EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | 6 Jahre |
Yossi Machtey | M | - |
Barnev, Inc.
Barnev, Inc. Information Technology ServicesTechnology Services Barnev, Inc. is a healthcare information technology company specializing in the development, manufacturing, and marketing of comprehensive monitoring and information solutions to clinicians and hospitals for labor and delivery. The firm is the first to market with delivery suite/product solutions that improve the clinical management of patients, and improve economic efficiency for its customers. Its first product, the BirthTrack™ Continuous Labor Monitoring System, is the most exciting innovation in labor progression monitoring since the Friedman Labor Curve was introduced over 50 years ago. The BirthTrack System is a revolutionary continuous labor monitoring technology that provides obstetric caregivers invaluable, precise, objective, real-time information about the physical progress of labor. | 22 Jahre |
Joy Weiss | F | 64 |
Inkspace Imaging, Inc.
Inkspace Imaging, Inc. Medical SpecialtiesHealth Technology Inkspace Imaging, Inc. develops magnetic resonance imaging surface receive coils. The company was founded by Ana Claudia Arias, Michael Lustingis and Joseph Corea in 2016 and is headquartered in Pleasanton, CA. | - |
Bradley Robert Kent | M | - |
emPower Health Equity, Inc.
emPower Health Equity, Inc. Medical/Nursing ServicesHealth Services emPower Health Equity, Inc. provides healthcare services. The company is headquartered in Tiburon, CA. | - |
Keith Fandrick | M | - |
AI Therapeutics, Inc.
AI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Gregory T. Went | M | 60 |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | - |
David Mahoney | M | 69 | 12 Jahre | |
Brian Best | M | - |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | - |
Natalie L. McClure | M | 71 | - | |
Robert W. Dean | M | 81 |
ViaLogy Plc
ViaLogy Plc Electronic Equipment/InstrumentsElectronic Technology ViaLogy Plc provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. Its product, QuantumRD, is a new technology for the discovery, validation, and recovery of oil and gas reservoirs. The company was founded in 1999 and is headquartered in Gifford, the United Kingdom. | 7 Jahre |
Uwe R. Feuersenger | M | - |
firstVentury Equity GmbH
| 8 Jahre |
Michael Urdea | M | 71 |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | - |
Jeremy S. Healey | M | - |
ViaLogy Plc
ViaLogy Plc Electronic Equipment/InstrumentsElectronic Technology ViaLogy Plc provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. Its product, QuantumRD, is a new technology for the discovery, validation, and recovery of oil and gas reservoirs. The company was founded in 1999 and is headquartered in Gifford, the United Kingdom. | - |
Sara Lewis | F | 56 | 2 Jahre | |
Stephen Shrewsbury | M | 67 | - | |
Michael Denis Coffee | M | 77 | 1 Jahre | |
Martha Demski | F | 71 | 7 Jahre | |
Michael McKenna | M | 61 |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | - |
Robert Michael Richey | M | 71 |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | 6 Jahre |
Jeffrey H. Knapp | M | 58 | 2 Jahre | |
John A. MacPhee | M | 56 | 8 Jahre | |
Richard H. Booth | M | 77 | 3 Jahre | |
Peter D. Hadrovic | M | 57 | - | |
Gayatri Sathyan | M | - | - | |
Melinda Griffith | F | 69 |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | 1 Jahre |
Kevin Deneen | M | - |
Calibrium Private Investments GmbH
Calibrium Private Investments GmbH Investment ManagersFinance Calibrium Private Investments GmbH (formerly Aeris Capital AG) is a venture capital firm with headquarters in Zurich, Switzerland. The firm was founded in 2006. | 6 Jahre |
Aaron D. Solomon | M | 59 |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | 1 Jahre |
Arnold Sternberg | M | - |
Calibrium Private Investments GmbH
Calibrium Private Investments GmbH Investment ManagersFinance Calibrium Private Investments GmbH (formerly Aeris Capital AG) is a venture capital firm with headquarters in Zurich, Switzerland. The firm was founded in 2006. | 4 Jahre |
Ted Tarasow | M | - |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | - |
David N. Hartford | M | - |
firstVentury Equity GmbH
| 2 Jahre |
Rhea J. Hamilton | F | 51 |
Calibrium Private Investments GmbH
Calibrium Private Investments GmbH Investment ManagersFinance Calibrium Private Investments GmbH (formerly Aeris Capital AG) is a venture capital firm with headquarters in Zurich, Switzerland. The firm was founded in 2006. | 4 Jahre |
Sharon Sakai | M | - | 2 Jahre | |
Gangadhara Ganapati | M | - | 5 Jahre | |
John B. Hollister | M | 62 |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | 2 Jahre |
Niall P. Davis | M | - |
firstVentury Equity GmbH
| 8 Jahre |
Anthony Rimac | M | 60 | 3 Jahre | |
Michael Kelly | M | - |
firstVentury Equity GmbH
| 8 Jahre |
Matthew Ferguson | M | 56 |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | 1 Jahre |
Sangita Ghosh | M | - | 6 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 54 | 78,26% |
Deutschland | 10 | 14,49% |
Schweiz | 4 | 5,80% |
Vereinigtes Königreich | 2 | 2,90% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- George Rehm
- Persönliches Netzwerk